GenIP Plc
LLSE:GNIP2.65
GBX
0.00
(0.00%)
ISIN
GB00BLCW2Q02
Return %
Stock
S&P 500
1Y
-87.95
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Melissa Mariel Cruz Claderon
- Full Time Employees
- 2
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 12 New Fetter Lane London GL United Kingdom EC4A 1JP
- IPO Date
- Oct 2, 2024
- Website
- genip.ai
- Similar Companies
- Business
- GenIP plc (GNIP.L) provides generative artificial intelligence analytic services to help companies, research institutions and venture funds assess and commercialise new technological discoveries. The company combines expert human technical review with proprietary GenAI algorithms to deliver verified insights through two complementary platform-based offerings: Invention Intelligence product suite, including Invention Evaluator for bespoke research reports assessing market potential of innovations, Invention Validator for premium market readiness testing with end-user validation at fees exceeding $12,000, Invention Prioritizer for portfolio-level assessments, and Competitive Intelligence Reports; and Vortechs, an executive recruitment platform using machine learning and natural language processing to match technology organisations with leaders experienced in commercialisation. GenIP serves large corporations, universities, government agencies, medical research institutions and venture funds across 25 countries on six continents, with headquarters in the United Kingdom. Founded prior to its AIM listing in 2024, the company has delivered over 5,800 reports to more than 300 clients worldwide. Recent developments include a December 2025 placing raising 300,000 pounds to fund platform automation integrating high-value products for margin growth and sales expansion in Asia and Latin America; launch of Invention Validator in October 2025 with first sale to a South African university; strategic partnerships such as with Brazil's technology park, new venture studio, and Chile's GreenTech Platform where GenIP serves as designated technology transfer supplier, plus 360 Social Impact Studios; major contract wins comprising a $350,000 Saudi Arabian deal for 400 assessments and a $65,000 Singapore contract; and international expansion with recurring university relationships validating product demand.